KEB-23746 Molecular and Synthetic Biology, 8 cr
Vastuuhenkilö
Ville Santala
Opetus
| Toteutuskerta | Periodi | Vastuuhenkilö | Suoritusvaatimukset |
| KEB-23746 2016-01 | 1 - 2 |
Suvi Santala Ville Santala |
Assignments on specific topics, seminars, and exam. |
Osaamistavoitteet
After passing the course the student can discriminate between different levels of genetic information from DNA to proteins. He/she will have an understanding of processes related to gene expression and linking genome to functioning of cells. The student can associate various cellular and environmental events to levels of gene expression and metabolism. He/she can explain the methods and rationale of manipulation of microbial genomes. The student will have a solid foundation in basic and modern biotechnology principles and technologies including synthetic biology and metabolic engineering.
Sisältö
| Sisältö | Ydinsisältö | Täydentävä tietämys | Erityistietämys |
| 2. | Genes and genetic information | ||
| 3. | Regulation of gene expression | Natural microbial circuits, Quorum sensing | |
| 4. | Recombinant DNA technology | Microbial cell factories | Genome-scale engineering and tools for genome construction and manipulation |
| 5. | Basics of synthetic biology | Genetic circuits | |
| 6. | Basics of metabolic engineering |
Oppimateriaali
| Tyyppi | Nimi | Tekijä | ISBN | URL | Lisätiedot | Tenttimateriaali |
| Book | Molecular Genetics of Bacteria | Dale, Park | 978-0-470-74184-9 | No | ||
| Book | Synthetic Biology - A Primer | Kitney (ed.) | 978-1-78326-878-8 | No |
Esitietovaatimukset
| Opintojakso | P/S | Selite |
| KEB-21000 Biokemia I | Mandatory | 1 |
| KEB-21100 Mikrobiologia I | Mandatory | 1 |
| KEB-21200 Molekyylibioteknologian perusteet | Mandatory | 1 |
1 . or corresponding courses.
Vastaavuudet
| Opintojakso | Vastaa opintojaksoa | Selite |
| KEB-23746 Molecular and Synthetic Biology, 8 cr | KEB-23747 Molecular and Synthetic Biology, 10 cr | |
| KEB-23746 Molecular and Synthetic Biology, 8 cr | KEB-23736 Industrial and Molecular Biotechnology, 8 cr |